Background and Purpose-Hyperglycemia and inflammation are involved in the progression of spontaneous intracerebral hemorrhage (sICH)-induced brain injury, but their role in predicting clinical outcome is not clear. We sought to determine whether elevation of white blood cell count (WBC), C-reactive protein (CRP), and blood glucose (BG) concentration at presentation prognosticate poor outcome in sICH patients. Methods-Between November 1, 2005 and October 31, 2009, 210 patients admitted to 2 intensive care units were prospectively consecutively evaluated after exclusion of patients with underlying inflammatory conditions. WBC, CRP, and BG were measured and ICH scores were calculated on first evaluation. Primary outcome was 30-day mortality. Secondary outcome was 30-day functional outcome using the Glasgow Outcome scale. Results-The median CRP concentration was 7.85 mg/L (interquartile range, 4.0 -12.0 mg/L), median WBC count was 8.05ϫ10 9 /L (interquartile range, 6.45-9.9ϫ10
S
pontaneous intracerebral hemorrhage (sICH; nontraumatic and without any underlying lesion) is often a devastating clinical event with limited effective therapies. 1 Despite the development of several clinical prognostic grading scales for ICH, the stratification of patients with sICH remains imperfect, showing modest levels of sensitivity and specificity. 2 Data collected from preclinical and clinical studies indicate that inflammatory processes 3 and hyperglycemia 4 are involved in sICH and in the progression of sICH-induced brain injury. A nonspecific systemic inflammatory response occurs after sICH, either as part of the process of brain damage 3 or in response to complications. 5 Several prospective studies in ischemic stroke patients have reported that increased levels of acute inflammatory markers, such C-reactive protein (CRP), 6 and white blood cell (WBC) count 7 are associated with increased risk of death or disability. The prognostic role of these inflammatory markers after sICH is less clear. 8 -10 Hyperglycemia represents a novel prognostic marker in acute sICH, 4 playing a major role in the pathogenesis of the acute inflammatory response in sICH patients. 11 Furthermore, these biomarkers reflect pathophysiological processes triggered by the hemorrhage that may not be accounted for by traditional prognostic factors. 12 The ICH score described by Hemphill et al 2 is a wellvalidated model for predicting clinical outcome prediction after sICH. This clinical grading scale is based on 5 clinical and neuroradiological variables: Glasgow coma scale, age, location of the hematoma, volume of the hematoma, and intraventricular extension of the hemorrhage. 13 It is unknown if the addition of markers of inflammation to this validated clinical prognostic model might improve the prediction of poor outcome after sICH.
The purpose of our study was to determine if markers of acute phase response-CRP, WBC, or glucose-are associated with poor outcome after sICH and whether the addition of these variables improves the prognostic accuracy of the ICH score.
Patients and Methods
We prospectively recruited all consenting patients admitted to 2 intensive care units (Sanatorio Pasteur, Catamarca, and Hospital Municipal "Leonidas Lucero," Bahia Blanca, Argentina) with a diagnosis of ICH within 24 hours after stroke onset between November 1, 2005 and December 31, 2009. sICH was defined as the sudden and spontaneous intraparenchymal bleeding confirmed by head CT scan, with or without intraventricular extension, in the absence of trauma or underlying structural lesions (vascular anomalies or tumors). To avoid confounding factors in the determination of inflammation markers, we excluded patients with a history of acute or chronic infections (Յ4 weeks before sICH), those with other concurrent comorbidities capable of increasing inflammation markers, and those with obvious signs and clinical evidence of acquired in-hospital infection. Patients referred after initial evaluation, those admitted Ͼ24 hours after sICH onset, and cases with missing data attributable to very early death were also excluded.
All patients were screened on hospital arrival, as soon as possible after presentation, according to a strict protocol. Definitions and diagnostic criteria and a detailed description of our study methodology have been published previously. 14 The Glasgow Coma scale score was used to assess initial neurological deficit and was determined after initial resuscitation. 15 Calculation of the ICH score was performed as described in the original description. 13 Medical management and surgical interventions followed current guidelines of the Stroke Council of the American Heart Association 1 and the European Stroke Initiative. 16 The following data were prospectively collected: demographic data, risk factors for sICH, comorbidities, blood pressure, ICH score, and CT scan findings.
The investigators reviewing the CT scans were blinded to the clinical information and classified neuroradiological findings according to localization (supratentorial or infratentorial), site of sICH (basal ganglia, thalamic, lobar, pontine, cerebellar, or other), volume of hematoma, midline shift, presence of intraventricular of the hemorrhage, and presence of hydrocephalus. All variables were determined on the initial CT scan. sICH hematoma volume was measured with the use of the ABC/2 method. 17 Midline shift was determined by measuring the displacement of the septum pellucidum from the midline. 18 
Measurement of Blood Markers
All routine biochemical, hematologic, and coagulation data were collected at entry. WBC counts were performed with Coulter counter. Blood glucose (BG) was determined by the glucose oxidase/ peroxidase method (BioSystems SA). CRP concentration was determined using a high-sensitivity immunoturbidimetric assay (Tinaquant; Roche Diagnostics) with a detection limit of 0.1 mg/L and a measuring range of 0.1 to 240 mg/L. The coefficient of variation ranged from 0.6% to 1.3% for the intra-assay precision and from 1.3% to 6% for the interassay reproducibility.
Outcome Measures and Follow-Up
The primary end point was mortality at 30 days. The Glasgow Outcome scale (GOS) was used to ascertain functional outcome at 30 days. Good outcome was defined as GOS score 4 to 5 and poor outcome was defined as GOS score 1 to 3. For patients in whom 30-day outcome was not available from medical records (nϭ4), follow-up data were obtained from follow-up visits. We were able to obtain current information on all included patients.
Investigators blinded to the results of biomarker testing collected all clinical, laboratory, and radiographic information, as well as the functional outcome category. Information regarding inflammation markers was not used to modify patient treatment during the hospital admission or the follow-up period.
This study was conducted according to the principles expressed in the Declaration of Helsinki. Informed consent was obtained from all subjects or, when not possible, from the next of kin. The study protocol was approved by our local Institutional Review Boards.
Statistical Analysis: Association Between Marker Levels and Baseline Features
Significance for intergroup differences was assessed by using the 2 test, by unpaired t test for continuous normally distributed variables, and by Mann-Whitney U test for non-normally distributed variables. Continuous variables are described as meanϮSD or median values with interquartile range. For the calculation of Pearson correlation coefficients, we logarithmically transformed positively skewed blood marker data to obtain a normal distribution.
Association Between Inflammation Marker Levels and Outcomes
The unadjusted associations between inflammatory marker level and outcome were assessed using 2 trend tests. Free survival between groups of patients defined by quartiles of inflammatory biomarkers was assessed by Kaplan-Meier survival curves and compared using log-rank trend tests.
We built a logistic regression model for the association of each inflammatory biomarker with the primary (mortality) and secondary (poor or good outcome) end points, adding the elements of the ICH score sequentially. We also examined logistic regression models for the association between individual biomarkers and mortality and functional outcome, adjusting in stepwise fashion for delay to blood sampling, vascular risk factors, surgery, and selected neuroradiological findings (domains that are not part of the ICH score). For these analyses, we compared the upper and lower quartiles of inflammatory marker levels for the entire sample and modeled the marker levels as linear variables.
Assessing the Performance of Prediction Models
The performance of prediction models based on ICH covariables with and without inflammation markers were assessed using several methods and metrics to reduce the risk of overoptimistic expectations of the inflammatory marker's performance. We assessed overall model performance for binary survival outcomes using Nagelkerke R 2 , likelihood ratio 2 , Bayes information criterion, and Akaike information criterion; model calibration was assessed using the Hosmer-Lemeshow statistic; discrimination ability was assessed using the c-index statistic together with newer methods such as reclassification tables 19 and the net reclassification improvement. 20 Decision-analytic measures were reported using the net benefit and the net benefit decision curves plotted to gain insight into the value of adding a novel predictor to an established model. 21 We used thresholds of 10% and 90% for predicted probability of poor outcome given the importance of being as certain as possible of a prognosis that often has immediate practical implications (eg, decision to proceed with surgical evacuation, restriction of care to palliative care only).
All tests were 2-sided. An association was considered significant if PϽ0.05. All statistical analyses were performed using SPSS version 17.0 (SPSS). We prepared this article using STROBE 22 and REMARK, 23 which are guidelines for reports of observational epidemiological studies and prognostic variables, respectively.
Results
During study period, 446 patients with clinical signs attributable to sICH were identified. Two-hundred thirty-six pa- 9 /L) and median BG concentration was 7.66 mmol/L (interquartile range, 6.11-10.83 mmol/L). The correlation coefficients between log e marker levels and delay from symptom onset to blood sampling were as follows: BG, Ϫ0.366; WBC, Ϫ0.289; and CRP, 0.140. These relationships remained statistically significant after adjusting for stroke severity and age (BG: rϭϪ0.252, PϽ0.0001; WBC: rϭϪ0.154, Pϭ0.029; CRP: rϭ0.153, Pϭ0.027). Thirty-nine (18.6%) patients underwent surgical hematoma evacuation. At 30 days, 63 (30%) patients were dead and 101 (48.1%) were dead or disabled. Deaths were attributable to the initial sICH or rebleeding in 55 cases (87.3%) and systemic complications in 8 cases (12.7%). Table 1 summarizes the baseline data. On arrival to the emergency department, patients who died had lower Glasgow Coma scale scores (PϽ0.0001), larger sICH volume (PϽ0.0001), greater midline shift (PϽ0.0001), and more frequent intraventricular extension (PϽ0.0001) and hydrocephalus (PϽ0.0001). WBC count (PϽ0.0001) and BG (PϽ0.0001) and CRP concentrations (Pϭ0.018) were significantly higher in patients who died. In general, the same variables were also associated with poor outcome (Supplemental Table 1 ).
The risk of death increased in each quartile of BG ( 2 trend Figure 2) . Table 2 shows the association between markers of acute phase response and mortality. In univariate analyses, all markers were significantly associated with death. However, after adjustment for ICH score variables (Glasgow Coma scale score, ICH volume, intraventricular hemorrhage, infratentorial origin of sICH, and age), time to blood sample after sICH, neuroradiological findings (midline shift and the presence of hydrocephalus), and surgery, the association only remained significant for CRP. In fact, the association between CRP and mortality became stronger after adjustment for confounding factors (Table 2) .
Patients with highest blood levels (last quartile) of CRP had a 23.91-fold (95% CI, 3.68 -59.33) increase in the risk of mortality compared with those with the lowest level. The adjusted increase in the odds of death for an increase of 1 mg/L of CRP was 4.99 per mg/L (95% CI, 1.64 -15.20 per mg/L; Table 3 ). None of the acute phase reactants were significantly associated with poor functional outcome at 30 days on adjusted analyses (Supplemental Tables 2 and 3) .
When we added the data of the acute phase response markers as continuous variables to the previously validated ICH score model (Table 4) , all biomarkers (BG, Pϭ0.0122; WBC count, Pϭ0.0060; and CRP, Pϭ0.0152) improved the discriminative ability of the model (the c-index increased significantly), albeit modestly. The greatest improvement of the ICH score was obtained by adding the CRP value (CRP value increased the model c 2 from 145 to 182). Overall performance also improved. Nagelkerke R 2 increased from 57% to 72% (Table 4) . Therefore, CRP had a better additional predictive value when compared to BG and WBC count.
We then compared the proportions of patients with predicted high (Ͼ90%) and low (Ͻ10%) risks of death according to the ICH score model, with and without the addition of inflammatory markers (Supplemental Table 5 ). The total reclassification attributable to the addition of single inflam- matory biomarkers to the variables in ICH was 19.0%, 20.5%, and 22.9% for BG, WBC count, and CRP, respectively. Based on the observed proportions, patients who were reclassified were placed into more appropriate categories, but these changes did not improve the overall prognostic accuracy of the ICH score (Supplemental Table 5 ). After addition of BG (net reclassification improvementϭ3.30%; Pϭ0.5720;
Cook reclassification test), WBC count (net reclassification improvementϭ2.19%; Pϭ0.5589) or CRP (net reclassification improvementϭ8.14%; Pϭ0.6123) to the ICH score, the net reclassification improvement was small and not significant. Similarly, the net benefit of the addition of inflammatory biomarkers to the ICH score was small in the lowest-risk patient category (Ͻ10%) and in the highest-risk patient category (90%) (Supplemental Table 5 ). However, the riskdecision curve shows that the net benefit would be much larger in the patients classified as being at low-to moderate risk using the ICH clinical score after the addition of inflammatory markers to the prognostic score ( Figure) .
Discussion
In this cohort of sICH patients assessed early in neurointensive care units, we found that higher levels of BG, CRP, and WBC count were significantly associated with 30-day death after sICH, whereas the association with poor outcome was less evident. Once corrected for confounding factors, only CRP was independently associated with 30-day mortality. The addition of CRP to the ICH score model increased the net reclassification improvement by Ϸ8%. However, the riskdecision curve to quantify the clinical usefulness of adding these inflammatory markers shows that the net benefit would be much larger (ie, the prognostic accuracy would be greater) in the patients classified as being at low to moderate risk by the ICH score alone. The inflammatory biomarkers had less prognostic impact for patients in the highest risk (Ͼ90%) category, in whom the severity of sICH is probably the major determinant of death, and in the lowest risk (Ͻ10%) category, in which comorbidities represent major determinants of prognosis. 5 All these performance measures suggest that CRP could be useful in predicting prognosis after sICH, particularly if added to ICH score. However, a strong and independent association of high CPR with poor outcome should be confirmed in validation cohorts of sICH patients before this variable can be confidently used in clinical practice. Human and animal model data support a strong role for leukocytes in sICH-induced brain injury. 3 Higher admission BG concentrations have been shown to dramatically increase brain edema and perihematomal cell death, 24 and it has been associated with hematoma expansion 25 and worse clinical outcome. 26 However, the associations of BG and WBC with mortality in our cohort were markedly attenuated after adjustment for indicators of sICH severity, suggesting that these measurements may represent surrogate biomarkers of sICH severity.
The association between mortality and CRP concentration appears more solid because it remained strong after adjustment for multiple confounding factors. Previous studies have only marginally evaluated the prognostic role of CRP after sICH with conflicting results, but differences in design may explain these differences. 8 -10 CRP improved mortality risk prediction in our cohort. Future studies in larger populations should be performed to further delineate the value of adding CRP to existing prognostic models. This study has methodological strengths, such as a relatively large patient population, prospective design, detailed follow-up and data collection, and mortality as principal outcome measure. The enrollment of patients after exclusion of possible confounders on inflammatory status also largely eliminates the confounding effect of inflammatory comorbidities on biomarker levels.
However, we also acknowledge that our study has limitations. We assessed inflammatory marker levels only within 24 hours of symptom onset. Early time of blood sampling could have reduced the strength of the association between inflammation markers, BG, and outcome. In patients with sICH, clinicians should not rely on a single point estimate when assessing the independent impact of hyperglycemia and acute inflammatory response on sICH outcome because this value probably grossly underestimates the true association. As illustrated by our previous study, a higher frequency of BG measurement, regardless of modality, is likely to facilitate the identification of hyperglycemic subgroups with different outcome. 14 To our knowledge, similar data are not currently available for CRP and WBC. Despite their associations with 30-day mortality, none of the tested biomarkers showed a significant association with poor functional outcome in survivors. More studies will be necessary to understand this discrepancy.
The ICH score provides a useful measure of outcome prediction in sICH and has been proven valuable in clinical practice. Whether it can be improved by including other simple and inexpensive measures previously has not been examined. All global measures of predictive accuracy were improved in a prediction model that included CRP. In particular, likelihood-based measures showed a preference for the ICH score model that included CRP. The net benefit curve analysis suggested that the inclusion of CRP in the prognostic model could be useful for patients with Ͼ10% and Ͻ90% predicted risk of death by the ICH score. Our conclusions would be strengthened by replication of our findings in a larger validation dataset.
Conclusions
Elevation of markers of acute inflammation and hyperglycemia are associated with higher risk of death in patients with sICH, but only CRP is an independent predictor of mortality in these patients. The value of adding CRP to validated prognostic scores deserves further evaluation.
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Patients
We prospectively recruited all consenting patients admitted to 2 Intensive Care All patients were screened upon hospital arrival, as soon as possible after presentation, according to a strict protocol consisting of a complete medical history, a full neurological examination, standardized blood tests, and CT scan of the brain or MR imaging. The Glasgow Coma Scale (GCS) was used to assess initial neurological deficit and determined after initial evaluation and resuscitation. 3 Determination of ICH score was performed as reported in the original description. 4 Medical management and surgical interventions followed current guidelines of the StrokeCouncil of the American Heart Association, 5 and the European Stroke Initiative. 6 According to our neurointensive care unit protocol, body temperature, heart and respiratory rate were measured on admission and then with intervals of two hours.
Measuring temperature was performed orally or rectally. WBC count was determined using 
Measurement of Blood Markers
All routine biochemistry, hematology and coagulation data were collected at entry.
WBC counts were done with Coulter counter. Blood glucose (BG) was determined by the glucose oxidase/peroxidase method (BioSystems SA, Barcelona, Spain) using an Alcyon 300
analyzer (Abbott Laboratories). Blood samples collected in EDTA were also assayed for CRP by use of a high-sensitivity immunoturbidimetric assay (Tina-quant; Roche Diagnostics) performed on a Modular D 914 analysis system (Mannheim, Germany) with a calibrator based upon the international calibrator CRM 470. The manufacturer claimed the detection limit to be 0.1 mg/l and the extended measuring range (with reruns) to be 0.1-240 mg/l. The coefficient of variation ranged from 0.6% to 1.3% for the intra-assay precision and from 1.3% to 6% for the inter-assay reproducibility.
Outcome measures and follow-up
The primary endpoint was mortality at 30 days. The Glasgow Outcome Scale (GOS) was used to ascertain functional outcome at 30 days. Good outcome was defined as GOS 4-5 and poor outcome as GOS 1-3.
Collection of all clinical, laboratory and radiographic information, together with final determination of outcome category, was performed by investigators blinded to the results of biomarker testing. Information regarding inflammation markers was not used to modify patient treatment during the hospital admission or the follow-up period.
Ethics Statement
This study was conducted according to the principles expressed in the Declaration of Helsinki. Informed consent was obtained from all subjects and the protocol was approved by our local Institutional Review Board.
Statistical Analysis Association between marker levels and baseline features
In a series of bivariate analyses, significance for intergroup differences was assessed by use of the  2 -test, by unpaired t-test for continuous normally distributed variables, and by Mann-Whitney U test for non-normally distributed variables. For the calculation of
Pearson correlation coefficients, we logarithmically transformed positively skewed blood marker data to obtain a normal distribution. We examined the relationship between biomarker level and delay to blood sampling using multivariable regression analysis.
Continuous variables are described as meanSD or median values with interquartile range (IQR).
Association between inflammation marker levels and outcomes
The unadjusted associations between inflammatory marker level and outcome was assessed using  2 -trend tests. Free survival between groups of patients defined by quartiles of inflammatory biomarkers were assessed by Kaplan Meier survival curves and compared with log-rank trend tests.
We built a logistic regression model for the association of each inflammatory biomarker with the primary (mortality) and secondary (poor or good outcome) endpoints, with the terms from the ICH score added sequentially. We also examined logistic regression models for the association between individual biomarkers and mortality and functional outcome, adjusting in stepwise fashion for delay to blood sampling, vascular risk factors, surgery and selected neuroradiological findings (domains not part of the ICH score). For these analyses, we compared the upper and lower quartiles of inflammatory marker levels for the entire sample and modeled the marker levels as linear variables.
Assessing the performance of prediction models
We assessed the additional contribution of those inflammatory markers that were significantly associated with mortality or poor outcome after adjustment for the ICH score variables. 4 The performance of prediction models comparing ICH co-variables with and without inflammation markers were assessed using a variety of methods and metrics to reduce the risk of overly optimistic expectations of the inflammatory marker's performance. We computed traditional measures for binary survival outcomes including Nagelkerke's R 2 , 10 the likelihood ratio  2 (LR- 2 ), the Bayes Information Criterion (BIC), 11 and the Akaike Information Criterion (AIC) 12 for overall model performance; the concordance (or c-index) statistic for discriminative ability 13 and the Hosmer-Lemeshow calibration statistic for calibration. 14 Discrimination abilities were assessed using the new measures recently proposed refinements of discrimination measures, including reclassification tables 15 and the Net Reclassification Improvement (NRI). 16 Finally, decisionanalytic measures were developed because predictive models have to be used for clinical decisions. We used the Net Benefit (NB) as a summary of the prediction performance and the net benefit decision curves were plotted to gain insight into the value of adding a novel predictor to an established model. 17 We used thresholds of 10% and 90% for predicted probability of poor outcome to be very certain of a good or poor outcome before avoiding treatments such as surgery or selecting patients for palliative care only.
All tests were 2-sided. An association was considered significant if P<0.05. All statistical analyses were performed using SPSS version 17.0 (SPSS Inc). We prepared this paper using STROBE, 18 and REMARK, 19 guidelines for reports of observational epidemiological studies and prognostic variables, respectively. 
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